Gannex Announces U.S. IND Approval and Initiation of Global Development of THR-β Agonist ASC41 for NASH ...Middle East

SHANGHAI, Feb. 24, 2021 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672), fully dedicated to the R&D and commercialization of new drugs in the field of nonalcoholic steatohepatitis (NASH), today announces the Investigational New Drug Application (IND)...

Hence then, the article about gannex announces u s ind approval and initiation of global development of thr b agonist asc41 for nash was published today ( Thursday 25/02/2021 - 04:00 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Gannex Announces U.S. IND Approval and Initiation of Global Development of THR-β Agonist ASC41 for NASH )

Also on site :

• Watch last video of ‘All That’ star Kianna Underwood who died in hit-and-run at 33
• Refugee-student housing project in EU state rocked by rape scandal
• AI cloud startup Runpod hits $120M in ARR — and it started with a Reddit post